{
    "clinical_study": {
        "@rank": "105719", 
        "acronym": "SWL", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "They will receive placebo"
            }, 
            {
                "arm_group_label": "Antioxidant group", 
                "arm_group_type": "Active Comparator", 
                "description": "They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week"
            }, 
            {
                "arm_group_label": "Calcium channel Blockers", 
                "arm_group_type": "Active Comparator", 
                "description": "They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week"
            }, 
            {
                "arm_group_label": "Angiotensin receptor blocker group", 
                "arm_group_type": "Active Comparator", 
                "description": "They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted to evaluate the protective effects and mechanisms of\n      antioxidants (vitamins A, C, E and Selenium), calcium channel blocker (Verapamil) and\n      angiotensin receptor blocker (Lozartan) against shock wave induced renal injuries."
        }, 
        "brief_title": "Renal Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shock Wave Lithotripsy Induced Renal Injury", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lithotripsy", 
        "condition_browse": {
            "mesh_term": "Wounds and Injuries"
        }, 
        "detailed_description": {
            "textblock": "The protective effect will be evaluated via estimation of the changes in renal tubular\n      enzyme (NGAL) and detection of albumen levels in urine. The mechanisms of protection will be\n      investigated by estimation of renal perfusion and functional changes using dynamic MRI."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Well functioning kidney (serum creatinine <1.2 mg/dl).\n\n          2. Solitary renal stone.\n\n          3. Size: 25 mm or less in the largest diameter.\n\n        Exclusion Criteria:\n\n          1. Contraindications to ESWL\n\n          2. Previous surgical treatment of renal stones.\n\n          3. Congenital renal anomalies.\n\n          4. Pediatric patients (age <15 years)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675362", 
            "org_study_id": "4228"
        }, 
        "intervention": [
            {
                "arm_group_label": "Antioxidant group", 
                "description": "They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week", 
                "intervention_name": "Antioxidant group", 
                "intervention_type": "Drug", 
                "other_name": "Selenium ACE"
            }, 
            {
                "arm_group_label": "Calcium channel Blockers", 
                "description": "They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week", 
                "intervention_name": "Calcium Channel Blockers", 
                "intervention_type": "Drug", 
                "other_name": "Verapamil"
            }, 
            {
                "arm_group_label": "Angiotensin receptor blocker group", 
                "description": "They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week", 
                "intervention_name": "Angiotensin receptor blocker group", 
                "intervention_type": "Drug", 
                "other_name": "Losartan"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "They will receive placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antioxidants", 
                "Selenium", 
                "Calcium, Dietary", 
                "Calcium Channel Blockers", 
                "Verapamil", 
                "Losartan", 
                "Vitamin A", 
                "Vitamins", 
                "Angiotensin Receptor Antagonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Extracorporeal shock wave lithotripsy (ESWL)", 
            "Kidney calculi", 
            "Renal protection", 
            "Antioxidants", 
            "Calcium channel blockers", 
            "Angiotensin receptor blockers"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mansoura", 
                    "country": "Egypt", 
                    "zip": "35516"
                }, 
                "name": "Urology and Nephrology Center"
            }, 
            "investigator": {
                "last_name": "Ahmed M. Elshal, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized Controlled Trial for Evaluating Renal Protective Effects of Antioxidants (Selenium and Vitamins A, C and E), Calcium Channel Blocker (Verapamil) and Angiotensin Receptor Blocker (Losartan) Against Extracorporeal Shock Wave Lithotripsy Induced Renal Injury", 
        "overall_contact": {
            "email": "kzsheir@hotmail.com", 
            "last_name": "Khaled Z. Sheir, MD", 
            "phone": "0020502262222", 
            "phone_ext": "1623"
        }, 
        "overall_contact_backup": {
            "email": "ar_el_nahas@yahoo.com", 
            "last_name": "Ahmed R. EL-Nahas, MD", 
            "phone": "00201221136899"
        }, 
        "overall_official": {
            "affiliation": "Mansoura University", 
            "last_name": "Ahmed R. EL-Nahas, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: Science and Technological Development Fund", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The protective effect will be evaluated via estimation of the changes in renal tubular enzyme (NGAL) and detection of albumen levels in urine.", 
            "measure": "Renal damage", 
            "safety_issue": "Yes", 
            "time_frame": "two hours and one week after Extracorporeal shock wave lithotripsy (ESWL)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675362"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mansoura University", 
            "investigator_full_name": "Ahmed R. EL-Nahas", 
            "investigator_title": "Assistant Professor of Urology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The mechanisms of protection will be investigated by estimation of renal perfusion and functional changes using dynamic MRI", 
            "measure": "The mechanisms of renal protection", 
            "safety_issue": "Yes", 
            "time_frame": "Before ESWL, 2 hours and 1 week after ESWL"
        }, 
        "source": "Mansoura University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mansoura University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}